<DOC>
	<DOCNO>NCT02832167</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab effective treatment advance metastatic cancer . The study evaluate clinical benefit rate Nivolumab subject 16 week enrollment . Various advance metastatic tumor type eligible enrollment . Subjects must receive prior standard care treatment cancer enrollment .</brief_summary>
	<brief_title>An Open Label Phase 2 Multicohort Trial Nivolumab Advanced Metastatic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Diagnosed advanced metastatic malignancy Received standard care treatment primary malignancy standard care treatment relapse cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathway . Subjects previously treat investigational anticancer therapy less 6 week prior first dose Nivolumab Subjects active , know , suspect autoimmune disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>